Venlafaxine

Venlafaxine is a synthetic antidepressant classified as a serotonin-norepinephrine reuptake inhibitor, a group of drugs that raise levels of two neurotransmitters involved in mood ^[1]. Chemically it is a phenylethylamine derivative and is usually supplied as its hydrochloride salt ^[1]. It is notable for a dose-dependent pharmacology: at lower doses it behaves much like a selective serotonin reuptake inhibitor, and its action on norepinephrine grows stronger as the dose is raised ^[1].

After it is absorbed, venlafaxine is converted by the liver enzyme CYP2D6 into an active metabolite called O-desmethylvenlafaxine, also known as desvenlafaxine, which shares its reuptake-inhibiting activity and is itself marketed as a separate antidepressant ^[1]. Because CYP2D6 activity varies widely between individuals, blood levels and response can differ considerably from person to person ^[1]. Both venlafaxine and its metabolite have relatively short half-lives and low protein binding ^[1].

Venlafaxine is approved for major depressive disorder and for generalized anxiety disorder, social anxiety disorder and panic disorder, and it is used off-label for conditions such as hot flashes and certain chronic pain and neuropathic states ^[1]. In a large network meta-analysis comparing antidepressants, venlafaxine ranked among the more effective agents, although it also carried a comparatively higher dropout rate than some alternatives ^[2]. It was approved for medical use in the United States in 1993 and was long sold under the brand name Effexor, with generic and extended-release versions following in later years ^[1].

Venlafaxine is a prescription-only medicine in the United States, the United Kingdom, Canada, Australia and the European Union ^[1]. Common side effects include nausea, dry mouth, sweating, sleep changes and sexual dysfunction, and at higher doses it can produce a mild, dose-dependent rise in blood pressure attributed to its effect on norepinephrine ^[1][3]. Like other antidepressants it carries warnings about a possible increase in suicidal thoughts in younger people, and it is associated with a relatively pronounced discontinuation syndrome, so stopping it suddenly can cause dizziness, irritability, flu-like feelings and sensory disturbances; a gradual taper is generally advised ^[1]. It should not be combined with monoamine oxidase inhibitors because of the risk of serotonin syndrome ^[1].

Venlafaxine is prescription only. Common effects include nausea, headache, dry mouth, sweating, insomnia and sexual dysfunction. It can raise blood pressure in a dose-related way, so pressure should be monitored, especially above 150 mg a day. Because it has a short half-life, stopping suddenly often causes a discontinuation syndrome with dizziness, brain zaps and flu-like feelings, so it must be tapered. Like other antidepressants it carries a boxed warning about suicidal thoughts in people under 25, and combining it with MAOIs or other serotonergic drugs can cause serotonin syndrome.

Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, has well-characterized pharmacokinetic interactions via CYP2D6. When combined with potent CYP2D6 inhibitors such as paroxetine, venlafaxine exposure increases substantially, with this interaction being particularly pronounced for the R-enantiomer ^[14]. CYP2D6 inhibition reduces conversion of venlafaxine to its active metabolite O-desmethylvenlafaxine, altering the overall pharmacodynamic profile.

Clarithromycin, another CYP2D6 inhibitor, produces similar elevated venlafaxine levels in patients with different CYP2D6 genotypes ^[15]. Pharmacodynamic interactions arise with other serotonergic agents (SSRIs, MAOIs, tramadol); although rare, serotonin syndrome is possible when venlafaxine is combined with these drugs or with linezolid. The interaction between venlafaxine and benzodiazepines or stimulants remains largely unstudied in controlled trials.

Checking a whole stack? Run it through interactions + stacks.

Venlafaxine was developed by the American pharmaceutical company Wyeth (then Wyeth-Ayerst, part of American Home Products) during the 1980s as part of an effort to create antidepressants that acted on more than one monoamine system. It received approval from the U.S. Food and Drug Administration in December 1993 under the brand name Effexor, becoming the first widely marketed serotonin-norepinephrine reuptake inhibitor and thereby founding the SNRI class.

An extended-release formulation, Effexor XR, followed in 1997, offering once-daily dosing and improved tolerability, and it went on to secure indications for generalized anxiety disorder, social anxiety disorder, and panic disorder in addition to major depression. The drug's active metabolite, desvenlafaxine, was later developed as a separate medicine in its own right. Over the following decades venlafaxine became one of the most widely prescribed antidepressants worldwide and was extensively studied as a nonhormonal treatment for hot flashes.

Venlafaxine enjoys a strong reputation as one of the more efficacious antidepressants; large network meta-analyses have repeatedly ranked it near the top of the class for reducing depressive symptoms. Clinicians particularly value its flexibility, since raising the dose progressively recruits noradrenergic activity and can help patients who respond only partially to serotonergic drugs alone.

Beyond mood and anxiety disorders it has earned a respected second life as an effective, well-tolerated option for menopausal and cancer-therapy-related hot flashes, giving relief to patients who cannot or prefer not to use hormones. Its limitations are honestly acknowledged: higher doses can raise blood pressure, and abrupt cessation is associated with a notably uncomfortable discontinuation syndrome, so gradual tapering is advised. On balance it remains a durable, evidence-backed choice valued for potency and versatility.